Meihua International Medical Technologies Co., Ltd. Announces Pricing of $36,000,000 Initial Public Offering
YANGZHOU, China, Feb. 16, 2022 /PRNewswire/ -- Meihua International Medical Technologies Co., Ltd. ("MHUA" or the "Company") (NASDAQ: MHUA), a reputable manufacturer and provider of Class I, II, and III disposable medical devices with operating subsidiaries in China, today announced the pricing of its initial public offering (the "Offering") of 3,600,000 ordinary shares at a public offering price of...
PharmaBlock Appoints Dr. Zhengtian Gu as Senior Vice President of Quality and Regulatory Affairs
NANJING, China, Feb. 16, 2022 /PRNewswire/ -- PharmaBlock (300725.SZSE), an innovative chemistry products and services provider to support drug discovery, development, and commercialization, announces the appointment of Dr. Zhengtian (Titan) Gu as Senior Vice President of Quality and Regulatory Affairs, responsible for corporate quality management and regulatory affairs. Dr. Gu has more than 20 years of R&D and management experience...
JIXING ANNOUNCES RECEIPT OF BREAKTHROUGH THERAPY DESIGNATION FOR AFICAMTEN IN CHINA
SHANGHAI, Feb. 16, 2022 /PRNewswire/ -- Ji Xing Pharmaceuticals Limited (JIXING), a clinical-stage biopharmaceutical company committed to bringing innovative medicines to underserved Chinese patients with serious and life-threatening diseases, today announced that the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) of the PRC has granted Breakthrough Therapy Designation for aficamten (CK-3773274) for the treatment of...
Sirnaomics Receives Safe to Proceed Letter for U.S. FDA Investigational New Drug Application for Systemic RNAi Therapeutic STP707 in Primary Sclerosing Cholangitis (PSC)
HONG KONG, Feb. 16, 2022 /PRNewswire/ -- Sirnaomics Ltd. (the "Company" or "Sirnaomics", stock code: 2257.HK), a leading biopharmaceutical company in discovery and development of RNAi therapeutics, announced that they have received the "safe to proceed" letter from the U.S. Food and Drug Administration (FDA) for the Company's investigational new drug (IND) application for STP707, its lead siRNA...
Nippon Express (China) Donates Protective Suits to China Railway Express Terminal Station in Xi’an
TOKYO, Feb. 16, 2022 /PRNewswire/ -- Nippon Express (China) Co., Ltd. (hereinafter "NX China"), a Nippon Express Holdings, Inc. Group company, has donated protective suits to the Xi'an International Inland Port Investment & Development Group (hereinafter "ITL Group") operating the rail terminal in Xi'an that serves as a key junction on the China Railway Express (hereinafter "CRE"). Logo:...
NIBIOHN, Shionogi Discover Host Immune-dependent Novel Anti-coronavirus Antibody
OSAKA, Japan, Feb. 16, 2022 /PRNewswire/ -- The National Institutes of Biomedical Innovation, Health and Nutrition (NIBIOHN; Ibaraki-shi, Osaka; Director-general: Yoshihiro Yoneda), in partnership with Shionogi & Co., Ltd. (Chuo-ku, Osaka; President and CEO: Isao Teshirogi), has successfully identified a novel antiviral antibody for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), its variants, and closely associated coronavirus species. Logo: https://kyodonewsprwire.jp/img/202202107244-O2-7jtU6NgB ...
A Breakthrough in Probiotic Therapy – Personalized Probiotics (Dispensing) Machine for a Balanced and Enhanced Immune System
BANGKOK, Feb. 16, 2022 /PRNewswire/ -- MED-CU has invented a Personalized Probiotics (Dispensing) Machine to deliver live microorganisms that have health benefits to treat patients with unclear health problems and those with microbial imbalances or "dysbiosis". Personalized Probiotics (Dispensing) Machine Based on the research "Comparative Microbiome Analysis for the Probiotics Development" with the support of the Thailand...
Delos Capital Announces $300 Million First Close of its Third Life Sciences Fund
HONG KONG, Feb. 15, 2022 /PRNewswire/ -- Delos Capital, a Hong Kong-headquartered life sciences venture capital fund with a global presence and investment mandate, announces the successful $300 million first close of its Fund III. The first close of Fund III was completed in only 6 months of fundraising and attracted commitments from reputable investors across US and Greater China,...
Goodwin Biotechnology Announces the Appointment of Darrin T. Schellin as Chief Executive Officer
PLANTATION, Fla., Feb. 15, 2022 /PRNewswire/ -- Goodwin Biotechnology, Inc. is pleased to announce a key appointment designed to accelerate its growth significantly and scale the company into the future. Darrin Schellin joins the company as Chief Executive Officer and will also be inducted as a member of the company's board of directors. Darrin will be based in Florida....
Travecta Therapeutics Appoints Leading Experts to Expand its Scientific Advisory Leadership Team
PRINCETON, N.J. and SINGAPORE, Feb. 15, 2022 /PRNewswire/ -- Travecta Therapeutics, Pte Ltd., a preclinical stage biopharmaceutical company pioneering a portfolio of product candidates engineered to cross the blood-brain-barrier, today announced significant expansion of the Scientific Advisory Board ("SAB"). The newly appointed members of the Scientific Advisory Board include: Stuart Grossman, MD; William...
